Karyopharm Rises After FDA Fast Track Designation for Selinexor

(Updates first paragraph with shares)

Karyopharm shares gain 22% in premarket trading Tuesday after the company said the US FDA granted Fast Track Designation to the development program of selinexor for the treatment of patients with a form of bone marrow cancer.

• Includes primary myelofibrosis, post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis
• Top-line data from a Phase 3 study is expected in 2025
• Karyopharm plans to expand its clinical development program in myelofibrosis by investigating selinexor in other JAKi-naive settings, such as novel combinations

To view the source of this information, click here

--With assistance from Angel Adegbesan.

To contact the ...